View Single Post
Old Mon Jun 6, 2016, 09:59 AM
bailie bailie is offline
Join Date: Dec 2013
Location: McMinnville,OR
Posts: 825

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes

Lenalidomide and azacitidine each have activity in myelodysplastic syndromes (MDS) patients, where both microenvironment and cell-regulatory mechanisms contribute to disease pathogenesis.

The overall response rate (per modified MDS International Working Group criteria) was 72%: 16 patients (44%) achieved a complete response(CR),and 10 (28%) had hematologic improvement. Median CR duration was 17 months (range, 3-39); median overall survival was 37months (range,7-55)for CR patients, and 13.6months for the entire cohort (range, 3-55). TET2/DNMT3A/IDH1/2 mutational status was associated with response in a limited number of patients. The lenalidomide/azacitidine combination is well-tolerated and highly active in treating greater-risk MDS. This study is registered at as NCT00352001. (Blood. 2012;120(25): 4945-4951)
age 70, dx RAEB-2 on 11-26-2013 w/11% blasts. 8 cycles Vidaza 3w/Revlimid. SCT 8/15/2014, relapsed@Day+210 (AML). Now(SCT-Day+1005). Prepping w/ 10 days Dacogen for DLI on 6/9/2017.
Reply With Quote